Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt No Debt
IMUC's Cash-to-Debt is ranked higher than
87% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. IMUC: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
IMUC' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: -10.70
Beneish M-Score: 2.38
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -162.65
IMUC's ROE % is ranked lower than
88% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. IMUC: -162.65 )
Ranked among companies with meaningful ROE % only.
IMUC' s ROE % Range Over the Past 10 Years
Min: -480.22  Med: -120.17 Max: -35.53
Current: -162.65
-480.22
-35.53
ROA % -97.59
IMUC's ROA % is ranked lower than
85% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. IMUC: -97.59 )
Ranked among companies with meaningful ROA % only.
IMUC' s ROA % Range Over the Past 10 Years
Min: -179.88  Med: -88.12 Max: -31.45
Current: -97.59
-179.88
-31.45
ROC (Joel Greenblatt) % -6860.96
IMUC's ROC (Joel Greenblatt) % is ranked lower than
84% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. IMUC: -6860.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
IMUC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -79400  Med: -16598.23 Max: 13323.94
Current: -6860.96
-79400
13323.94
3-Year EPS without NRI Growth Rate 7.20
IMUC's 3-Year EPS without NRI Growth Rate is ranked higher than
61% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. IMUC: 7.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
IMUC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -28.1  Med: -4.4 Max: 81.7
Current: 7.2
-28.1
81.7
GuruFocus has detected 2 Warning Signs with ImmunoCellular Therapeutics Ltd $IMUC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» IMUC's 10-Y Financials

Financials (Next Earnings Date: 2017-08-22 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

IMUC Guru Trades in

IMUC Guru Trades in

IMUC Guru Trades in

Q4 2016

IMUC Guru Trades in Q4 2016

Jim Simons 97,604 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with IMUC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 8731
Compare:OTCPK:PPCHD, OTCPK:RVVTF, OTCPK:TSOI, OTCPK:MYMMF, OTCPK:VDQSF, OTCPK:CRYO, OTCPK:PVOTF, OTCPK:NMUS, OTCPK:STLT, OTCPK:BITRF, OTCPK:AYTU, OTCPK:MNTM, OTCPK:CLCS, OTCPK:MYMX, OTCBB:RGBP, OTCPK:WLXMF, NAS:CERC, OTCPK:REPCF, NAS:TRPX, AMEX:APHB » details
Traded in other countries:KOL1.Germany,
Headquarter Location:USA
ImmunoCellular Therapeutics Ltd is a clinical-stage biotechnology company that develops immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors.

ImmunoCellular Therapeutics Ltd.

Ratios

vs
industry
vs
history
PB Ratio 1.39
IMUC's PB Ratio is ranked higher than
78% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. IMUC: 1.39 )
Ranked among companies with meaningful PB Ratio only.
IMUC' s PB Ratio Range Over the Past 10 Years
Min: 0.23  Med: 5.94 Max: 18.01
Current: 1.39
0.23
18.01
EV-to-EBIT 0.01
IMUC's EV-to-EBIT is ranked higher than
99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. IMUC: 0.01 )
Ranked among companies with meaningful EV-to-EBIT only.
IMUC' s EV-to-EBIT Range Over the Past 10 Years
Min: -19.9  Med: -4.7 Max: 2
Current: 0.01
-19.9
2
EV-to-EBITDA 0.01
IMUC's EV-to-EBITDA is ranked higher than
99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. IMUC: 0.01 )
Ranked among companies with meaningful EV-to-EBITDA only.
IMUC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.9  Med: -4.7 Max: 2
Current: 0.01
-19.9
2
Current Ratio 4.14
IMUC's Current Ratio is ranked higher than
51% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. IMUC: 4.14 )
Ranked among companies with meaningful Current Ratio only.
IMUC' s Current Ratio Range Over the Past 10 Years
Min: 0.98  Med: 11.39 Max: 69.45
Current: 4.14
0.98
69.45
Quick Ratio 3.78
IMUC's Quick Ratio is ranked higher than
50% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. IMUC: 3.78 )
Ranked among companies with meaningful Quick Ratio only.
IMUC' s Quick Ratio Range Over the Past 10 Years
Min: 0.98  Med: 11.18 Max: 69.45
Current: 3.78
0.98
69.45

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -33.70
IMUC's 3-Year Average Share Buyback Ratio is ranked lower than
83% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. IMUC: -33.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IMUC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -51.6  Med: -30.2 Max: -19.3
Current: -33.7
-51.6
-19.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 12.35
IMUC's Price-to-Net-Cash is ranked lower than
77% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. IMUC: 12.35 )
Ranked among companies with meaningful Price-to-Net-Cash only.
IMUC' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.02  Med: 4.45 Max: 74.22
Current: 12.35
1.02
74.22
Price-to-Net-Current-Asset-Value 3.21
IMUC's Price-to-Net-Current-Asset-Value is ranked higher than
67% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. IMUC: 3.21 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
IMUC' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.01  Med: 2.66 Max: 70.8
Current: 3.21
1.01
70.8
Price-to-Tangible-Book 1.39
IMUC's Price-to-Tangible-Book is ranked higher than
83% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. IMUC: 1.39 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
IMUC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1  Med: 2.01 Max: 70.64
Current: 1.39
1
70.64
Earnings Yield (Greenblatt) % 3290.45
IMUC's Earnings Yield (Greenblatt) % is ranked higher than
100% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. IMUC: 3290.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IMUC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 49.5  Med: 72.1 Max: 6268.01
Current: 3290.45
49.5
6268.01

More Statistics

EPS (TTM) $ -8.24
Beta0.63
Short Percentage of Float12.26%
52-Week Range $1.83 - 12.39
Shares Outstanding (Mil)3.46

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) -8.57
EPS without NRI ($) -8.57
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for IMUC

Headlines

Articles On GuruFocus.com
3 Different Companies With 3 Different Approaches to Tumors Apr 24 2017 

More From Other Websites
ImmunoCellular Therapeutics and Memgen Announce Letter of Intent for Potential Joint Immuno-Oncology... Mar 23 2017
ImmunoCellular Therapeutics Receives Audit Opinion With Going Concern Explanation Mar 14 2017
Edited Transcript of IMUC earnings conference call or presentation 9-Mar-17 10:00pm GMT Mar 10 2017
ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and... Mar 09 2017
ImmunoCellular Therapeutics to Report Fourth Quarter and Full Year 2016 Financial Results on March... Mar 06 2017
ImmunoCellular Therapeutics Provides Update on ICT-107 Phase 3 Glioblastoma Trial and Announces... Mar 06 2017
Latest Reports on ImmunoCellular Therapeutics and Neuralstem as Biotech Industry Scrutiny Grows... Jan 12 2017
ImmunoCellular Therapeutics Announces Management Changes Dec 14 2016
ImmunoCellular Therapeutics Reports Updated Immune Monitoring Data from ICT-107 Phase 2 Trial in... Nov 21 2016
ImmunoCellular Therapeutics Announces Third Quarter 2016 Financial Results and Provides Research and... Nov 10 2016
ImmunoCellular Therapeutics to Report Third Quarter 2016 Financial Results on November 10, 2016 Nov 02 2016
Edited Transcript of IMUC earnings conference call or presentation 22-Aug-16 9:00pm GMT Aug 23 2016
ImmunoCellular Therapeutics Announces Second Quarter 2016 Financial Results Aug 22 2016
ImmunoCellular Therapeutics to Report Second Quarter 2016 Financial Results on August 22, 2016 Aug 17 2016
ImmunoCellular Therapeutics Announces Pricing of $7.4 Million Public Offering Aug 09 2016
ImmunoCellular Therapeutics Reports Progress in Two Lead Cancer Immunotherapy Programs Jul 25 2016
ImmunoCellular Therapeutics Treats First Patient in ICT-107 Phase 3 Registrational Trial in Newly... Jun 07 2016
ImmunoCellular Therapeutics to Present at Marcum MicroCap Conference on June 2, 2016 May 23 2016
BioLife Solutions and MNX Global Logistics Partner to Support ImmunoCellular Therapeutics with Cold... May 19 2016
ImmunoCellular Therapeutics Announces First Quarter 2016 Financial Results May 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)